Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pelthos Therapeutics ( (PTHS) ) has issued an update.
On March 19, 2026, Pelthos Therapeutics reported fourth-quarter and full-year 2025 results, highlighting the July 2025 launch of ZELSUVMI, which generated $16.2 million in net sales through year-end and drove a 28% sequential revenue increase to $9.1 million in the fourth quarter. From launch through December 31, 2025, 8,948 units were dispensed from 2,712 unique prescribers, with quarterly volumes up 129% in the fourth quarter versus the third quarter, underscoring strong early uptake despite seasonal softness in molluscum contagiosum treatment.
The company continued to build a pediatric-focused infectious dermatology platform, acquiring XEPI in November 2025 and XEGLYZE in January 2026 to complement ZELSUVMI and broaden its addressable market. Pelthos also bolstered its balance sheet with an $18 million private convertible notes financing in November 2025 and a $50 million senior secured term loan facility in January 2026, drawing $30 million, while reducing quarterly SG&A, narrowing operating losses, and improving adjusted EBITDA as it moves toward positive cash flow and scales its expanded 64-representative sales force.
Pelthos ended 2025 with $18 million in cash, excluding the January 2026 term debt funding, and 8.9 million shares outstanding on an as-converted basis, reflecting a capital strategy geared toward managing dilution as it funds commercial expansion. Management framed the improved operating metrics, portfolio expansion, and added financing capacity as positioning the company to capitalize on large unmet markets in pediatric infectious skin diseases and to leverage existing commercial infrastructure with limited incremental overhead.
The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
Spark’s Take on PTHS Stock
According to Spark, TipRanks’ AI Analyst, PTHS is a Neutral.
The score is held back primarily by weak financial performance (large losses and ongoing cash burn) and a soft technical setup (below key short-to-mid moving averages). Offsetting factors include a constructive earnings update tied to the ZELSUVMI launch and supportive corporate actions that improve funding and expand the commercial portfolio, though valuation support is limited by negative earnings.
To see Spark’s full report on PTHS stock, click here.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on differentiated cutaneous infectious disease products addressing unmet patient needs. Its lead product, ZELSUVMI, is the first and only prescription therapy approved for at-home treatment of molluscum contagiosum, complemented by XEPI for impetigo and XEGLYZE for head lice, targeting mainly pediatric populations in the U.S.
Based in Durham, N.C., and listed on the NYSE American under the ticker PTHS, Pelthos is building a portfolio of FDA-approved topical treatments for common yet undertreated infectious skin conditions. The company is expanding its U.S. sales force to support commercialization and leverage synergies across its pediatric-focused dermatology franchise.
Average Trading Volume: 11,330
Technical Sentiment Signal: Buy
Current Market Cap: $77.91M
See more insights into PTHS stock on TipRanks’ Stock Analysis page.